Publications
359
Citations
15,890
Est. group size
—
Recurring co-author estimate
Active years
23
Publishing since 2004
Raj Vuppalanchi studies liver diseases, focusing on fatty liver disease (now called MASLD/MASH, related to metabolic dysfunction), bile-duct disorders such as primary sclerosing cholangitis, and liver injury caused by drugs and vaccines. Much of the work involves clinical trials testing new medications and imaging methods (such as MRI-based measurements) to diagnose and track liver disease and its outcomes. The research combines drug testing, imaging biomarkers, and genetic factors linked to liver injury.
Publication activity has been steady and high across the last decade, generally ranging from about 17 to over 30 papers per year.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Global Longitudinal Assessment of <scp>MASLD</scp> Using Magnetic Resonance Elastography ( <scp>GOLDMINE</scp> ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in <scp>MASLD</scp> Clinical Outcomes
Alimentary Pharmacology & Therapeutics · 2026
- The Prognostic Utility of Quantitative Magnetic Resonance Cholangiopancreatography in Patients With PSC: A Systematic Review With Structured Evidence Synthesis
Journal of Computer Assisted Tomography · 2026
- Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
Institutional Repositories DataBase (IRDB) · 2026
- Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
The Lancet. Gastroenterology & hepatology · 2025
- Clinical and Genetic Associations in Cephalosporin‐Induced Liver Injury: Insights From the Drug‐Induced Liver Injury Network
Alimentary Pharmacology & Therapeutics · 2025
- Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis
Clinical Gastroenterology and Hepatology · 2025
- Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide
JHEP Reports · 2025
- Recent Advances in Primary Biliary Cholangitis Treatment
Clinics in Liver Disease · 2025
- WED-383 Change in cT1 following interventions in metabolic dysfunctionassociated steatotic liver disease: a systematic review and metaanalysis
Journal of Hepatology · 2025
- Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
Diabetologie und Stoffwechsel · 2025
- Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus
Clinics in Liver Disease · 2025
- Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
Alimentary Pharmacology & Therapeutics · 2025
- ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study
UNC Libraries · 2025
- DRESS Syndrome in Patients With Drug-Induced Liver Injury: Characteristics and HLA Risk Factors
The American Journal of Gastroenterology · 2025
- LBO-006 Belapectin at 2 mg/kg/LBWreduces varices development in MASH cirrhosis with portal hypertension: results from the NAVIGATE trial
Journal of Hepatology · 2025
- Gastroenterology×26
- Journal of Hepatology×25
- The American Journal of Gastroenterology×19
- Alimentary Pharmacology & Therapeutics×15
- Clinical Gastroenterology and Hepatology×13
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile